4SCAR-T Therapy Post CD19-targeted Immunotherapy

NCT04430530 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

CD19 Negative B-cell Malignancies

Interventions

BIOLOGICAL: Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20

Sponsor

Shenzhen Geno-Immune Medical Institute

Collaborators

[object Object]
[object Object]
[object Object]